


L23 -- ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:294877 CAPLUS
DOCUMENT NUMBER: 124:343341
TITLE: Preparation of cyclic polyamines as antiviral agents
INVENTOR(S): Iwata, Masaaki; Yamamoto, Naoki; Nakajima, Hideki
PATENT ASSIGNEE(S): Rikagaku Kenkyusho, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 35 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08027129	A2	19960130	JP 1994-165028	19940718


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Cyclic polyazaalkanes, in which 3-20 C2, C3, or C4 alkylene chains and NH are alternately linked, are prep'd. Thus, the title compd. (I.8HBr) was prep'd. by condensation of 1,5,9-triazacyclododecane deriv. (III; Ts = p-toluenesulfonyl) with 1,3-dibromopropane in the presence of NaHCO₃ at 70.degree. for 4 days followed by detosylation. I.8HBr and another title compd. (II.20HBr) showed ED₅₀ of 2.5 and 0.67 .mu.M for inhibiting the death of HIV-infected MT-4 cells (vs. 0.019 .mu.M for AZT) and 50% cytotoxic concn. of 470 and 8.6 .mu.M, resp., against MT-4 cells (vs. 247.25 .mu.M).
IT 164913-15-9P 164913-31-9P 164913-40-0P
167080-92-4P 167080-93-5P 167080-99-1P
176493-19-9P 176493-21-3P 176493-22-4P
176493-23-5P 176493-25-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of cyclic polyazaalkanes as antiviral agents)
RN 164913-15-9 CAPLUS
CN 1,5,9-Triazacyclododecane, 1,5-bis[(4-methylphenyl)sulfonyl]-9-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 164913-31-9 CAPLUS
CN 1,5,9-Triazacyclododecane, 1,5-bis[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 164913-40-0 CAPLUS
CN 1,5,9-Triazacyclododecane, 1-(3-bromopropyl)-5,9-bis[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)





RN 167080-92-4 CAPLUS

CN 1,5,9,13,17-Pentaazacycloheneicosane, 9-[3-[5,9-bis[(4-methylphenyl)sulfonyl]-1,5,9-triazacyclododec-1-yl]propyl]-1,5,13,17-tetrakis[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 167080-93-5 CAPLUS
CN 1,5,9-Triazacyclododecane, 1,1'-(1,3-propanediyl)bis[5,9-bis[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A





RN 167080-99-1 CAPLUS

CN 5,9-Diaza-1-azoniacyclododecane, 1,1-bis[3-[5,9-bis[(4-methylphenyl)sulfonyl]-1,5,9-triazacyclododec-1-yl]propyl]-5,9-bis[(4-methylphenyl)sulfonyl]-, bromide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● Br⁻


RN 176493-19-9 CAPLUS

CN 1,5,9,13,17,21,25-Heptaazacyclooctacosane, 13-[3-[5,9-bis[(4-methylphenyl)sulfonyl]-1,5,9-triazacyclododec-1-yl]propyl]-1,5,9,17,21,25-hexakis[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 176493-21-3 CAPLUS

CN 1,4,7,11-Tetraazacyclotetradecane, 4,11-bis[3-[5,9-bis[(4-methylphenyl)sulfonyl]-1,5,9-triazacyclododec-1-yl]propyl]-1,7-bis[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 176493-22-4 CAPLUS

CN 1,5,9,13-Tetraazacyclohexadecane, 1,9-bis[3-[5,9-bis[(4-méthylphényle)sulfonyl]-1,5,9-triazacyclododec-1-yl]propyl]-5,13-bis[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 176493-23-5 CAPLUS

CN 1,5,9,14,18,22-Hexazaazacyclohexacosane, 5,18-bis[3-[5,9-bis[(4-methylphenyl)sulfonyl]-1,5,9-triazacyclododec-1-yl]propyl]-1,9,14,22-tetrakis[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


PAGE 1-A.



PAGE 1-B




PAGE 2-A




RN 176493-25-7 CAPLUS

CN 1,4,7-Triaza-11-azoniacyclotetradecane, 4,11,11-tris[3-[5,9-bis[(4-methylphenyl)sulfonyl]-1,5,9-triazacyclododec-1-yl]propyl]-1,7-bis[(4-methylphenyl)sulfonyl]-, bromide (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Br⁻

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.